Pengpeng Qu - Publications

Overall survival and long-term safety of olaparib maintenance in patients with platinum-sensitive relapsed ovarian cancer: final analyses of phase III L-MOCA trial.

Journal: Journal of ovarian research

Published: February 10, 2026

Analysis of the current situation and influencing factors of work-related musculoskeletal disorders among hospital medical staff

Journal: Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases

Published: February 01, 2026

Integrating the Silva pattern into clinical practice: a prognostic tool for tailoring surgery and adjuvant therapy in cervical adenocarcinoma.

Journal: Cancer treatment and research communications

Published: January 26, 2026

Pegylated liposomal doxorubicin plus carboplatin versus paclitaxel plus carboplatin as first-line therapy for epithelial ovarian cancer (CGCS-04): a multicenter, randomized clinical trial.

Journal: Therapeutic advances in medical oncology

Published: September 21, 2025

Correction: CS Ratio is an immune-related prognostic biomarker for cervical cancer.

Journal: Frontiers in oncology

Published: September 02, 2025

Pan-Cancer Analysis of WRN: From Multi-Omics Biomarker Discovery to Therapy-Guiding Functional Evidence.

Journal: OncoTargets and therapy

Published: September 01, 2025

Impact of single-site distant metastases on prognosis in advanced ovarian cancer: a Surveillance, Epidemiology, and End Results population-based study.

Journal: Translational cancer research

Published: June 24, 2025

Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial.

Journal: Nature communications

Published: April 21, 2025

Laparoscopic anterior pelvic exenteration following concurrent chemoradiotherapy: how I do it.

Journal: The British journal of surgery

Published: March 17, 2025

Promoting tumor cell secretion of IL18 to induce reprogramming of tumor-associated macrophages - The novel anticancer mechanism of anlotinib in ovarian cancer.

Journal: Biochemical pharmacology

Published: January 16, 2025

The development and validation of a novel programmed cell death-related signature based on machine learning analysis of 15 programmed cell death patterns for predicting prognosis and therapeutic response in high-grade serous ovarian carcinoma.

Journal: Translational cancer research

Published: December 30, 2024

CS Ratio is an immune-related prognostic biomarker for cervical cancer.

Journal: Frontiers in oncology

Published: December 18, 2024